Furthermore, our integrative analysis of real-world SCLC cohorts demonstrated that patients with high IFITM3 expression had significantly longer PFS after treatment with anti-PD-1 inhibitors. The gene discussed is IFITM3; the disease is small cell lung carcinoma.